Transgenic Technology

Cheatsheet Content

### Transgenic Mice: Overview Transgenic mice are essential models in biomedical research, allowing the study of gene function, disease mechanisms, and therapeutic interventions. Various methods exist for generating them, each with unique advantages and limitations. ### Retroviral Gene Transfer Retroviruses integrate their genetic material into host cell chromosomes, making them effective gene delivery vehicles. #### 1. Biological Basis * **Definition:** RNA viruses that use reverse transcriptase to integrate DNA into host genome. * **Advantage:** Highly efficient integration, evolved for stable genomic insertion. * **Mechanism:** Uses viral tropism (cell entry) while removing replication genes for safety. #### 2. Viral Structure & Composition * **Genome:** Two copies of positive-sense, single-stranded RNA (7-12 kb). * **Essential Genes:** * `gag`: Capsid and matrix proteins. * `pol`: Reverse transcriptase and integrase. * `env`: Envelope glycoproteins (cell entry). * **Structure:** Lipid bilayer envelope with envelope proteins. #### 3. Mechanism of Integration 1. **Binding:** Envelope glycoprotein binds to target cell receptors. 2. **Entry:** Viral core enters cytoplasm. 3. **Uncoating:** Viral RNA and enzymes released. 4. **Reverse Transcription:** Reverse transcriptase synthesizes dsDNA from RNA. 5. **Nuclear Entry:** dsDNA enters nucleus. 6. **Integration:** Integrase inserts viral DNA (provirus) into host chromosome. 7. **Replication:** Provirus replicates with host DNA. #### 4. Vector Construction for Safety * **Replication-defective:** `gag`, `pol`, `env` genes deleted. * **Transgene:** Replaced with gene of interest + selectable marker (e.g., `Neor`). * **LTRs:** Long Terminal Repeats retained for transcription and integration. * **Safety:** Cannot produce infectious particles without helper cells. * **Size Constraint:** Accommodates up to ~8 kb insert DNA. #### 5. Transgenic Mouse Production 1. **Vector Production:** Replication-defective vector introduced into packaging cells (stably expressing `gag`, `pol`, `env`). Produces high-titer virus. 2. **Embryo Exposure:** Early-stage embryo (4-8 cell) exposed to viral preparation. 3. **Integration:** Transgene integrates into embryonic genome. 4. **Embryo Transfer:** Cultured embryos transferred to pseudopregnant recipient. #### 6. Integration & Expression * **Frequency:** Typically single integration event per embryo. * **Copy Number:** Usually 1-2 copies at one chromosomal location. * **Randomness:** Random throughout genome. * **Position Effects:** Expression highly variable (10-100 fold) due to chromatin environment. * Euchromatin (open) → high expression. * Heterochromatin (closed) → silenced expression. #### 7. Advantages * Broad host range. * High efficiency (1-10% of embryos become transgenic). * Stable, heritable integration. * Simple entry mechanism. * Suitable for germline transmission. #### 8. Limitations * **Cell Cycle Restriction:** Only infects dividing cells. * **Limited Insert Size:** Max ~8 kb. * **Insertional Mutagenesis:** Random integration can disrupt endogenous genes. * **Variable Expression:** Position effects make expression unpredictable. * **Safety:** Risk of reactivation or creation of infectious virus (low). ### DNA Microinjection A direct, vector-independent method of introducing DNA into the pronucleus of a fertilized egg. #### 1. Principle & Significance * **Method:** Direct injection of exogenous DNA into the male pronucleus of a fertilized egg. * **Integration:** Through non-homologous end joining (NHEJ) by cellular DNA repair machinery. * **Timing:** Critical to inject before pronuclear fusion (10-15 hours post-fertilization). * **Randomness:** Integration is random, often as multiple tandem copies (concatemers). * **Status:** Most widely used method for transgenic mice. #### 2. Procedural Protocol 1. **Superovulation & Egg Collection:** * Superovulation of females (PMSG + HCG) for high egg yield (30-50 eggs). * Eggs collected 13-15 hours post-HCG. * Cumulus cells removed. 2. **Fertilization:** In vitro fertilization (IVF) to obtain fertilized eggs with visible pronuclei. 3. **Microinjection:** * Equipment: Microscope with micromanipulators, fine micropipettes (0.5-1 µm). * DNA: 1-5 ng/µL concentration, 1-2 pL injected. * Target: Male pronucleus (larger, easier, higher success). * Speed: 10-30 seconds per egg. 4. **Post-Injection Culture:** Embryos cultured for 12-24 hours (to 2-cell stage) for recovery and DNA integration. 5. **Embryo Transfer:** 10-20 embryos transferred to pseudopregnant recipient female. #### 3. Integration & Molecular Outcomes * **Frequency:** 1-3% of injected embryos produce transgenic founders. * **Embryonic Loss:** ~50-70% due to injection trauma. * **Integration Pattern:** Usually single site with 5-10 tandem copies (concatemers). * **Randomness:** Completely random throughout the genome. #### 4. Mosaicism * **Definition:** Transgene present in some cells but not all of the founder animal. * **Cause:** Integration occurs after the first cell division has begun. * **Implication:** Mosaic founders transmit the transgene to only some offspring. Requires breeding to establish non-mosaic lines. #### 5. Advantages * **Simplicity:** No vectors or special constructs needed. * **Universal:** Any DNA sequence can be injected (no size restriction within reason). * **Broad Species Range:** Works in mice, rats, rabbits, pigs, cattle, etc. * **Stable Integration:** Heritable through germline. #### 6. Limitations * **Low Efficiency:** 1-3% success rate. * **Embryo Loss:** High due to trauma. * **Random Integration:** Cannot target specific loci. * **Position Effects:** Highly variable expression. * **Mosaicism:** Frequent, requires screening. * **Labor Intensive:** Requires skilled personnel and equipment. * **Insertional Mutagenesis:** Can disrupt endogenous genes. #### 7. Transgene Expression Control * **Promoters:** Strong constitutive (CMV), tissue-specific (MMTV), inducible (Doxycycline). * **Mitigation:** Locus Control Regions (LCRs) and chromatin insulators improve consistency but don't eliminate variation. * **Practical:** Screen multiple founder lines for optimal expression. ### Embryonic Stem (ES) Cell Method & Homologous Recombination This method allows for precise, targeted genetic modifications, such as knockouts and knockins. #### 1. ES Cells: Derivation & Characteristics * **Source:** Inner cell mass of blastocyst (~3.5 days). * **Pluripotency:** Can differentiate into all cell types and germ layers. * **Self-renewal:** Divide indefinitely in culture. * **Germline Contribution:** Can contribute to germline when injected into host blastocyst. * **Modifiability:** Can be transfected and undergo homologous recombination. #### 2. Targeting Vectors: Design & Components Targeting vectors contain specific elements for homologous recombination: 1. **5' Homology Arm:** 5-10 kb, matches upstream region of target gene. 2. **Insert Sequence:** Modified gene (e.g., exon deletion for knockout, novel sequence for knockin). 3. **3' Homology Arm:** 5-10 kb, matches downstream region of target gene. 4. **Positive Selection Marker:** `Neor` (neomycin resistance) for G418 selection. 5. **Negative Selection Marker:** `HSV-tk` (herpes simplex virus thymidine kinase) outside homology arms. #### 3. Positive-Negative Selection Strategy * **Positive Selection (G418):** Selects for all cells that have taken up the vector (both homologous recombinants and random integrations). * **Negative Selection (Ganciclovir):** Kills cells with random integration (which retain `HSV-tk`). Homologous recombinants lose `HSV-tk` and survive. * **Outcome:** Enriches for homologous recombinants (>90% of survivors). #### 4. Transfection Methods * **Electroporation (Primary):** Electrical pulses create transient pores for DNA entry. Efficient (5-20% transfection). * **Lipofection:** Cationic liposomes complex with DNA. Less efficient than electroporation for ES cells. #### 5. From Targeted ES Cells to Chimeric Mice 1. **ES Cell Preparation:** Correctly targeted ES cells (verified by PCR/Southern blot) are expanded. 2. **Blastocyst Injection:** 15-20 ES cells injected into the blastocele cavity of a host blastocyst (from a different mouse strain, e.g., light-colored coat). 3. **Embryo Transfer:** Injected blastocysts transferred to pseudopregnant recipient. 4. **Chimeric Development:** Animal composed of cells from both host and ES cells (e.g., mosaic coat pattern). 5. **Germline Transmission:** Chimeric mice are bred with wildtype animals. Offspring are genotyped to confirm transmission of the targeted allele. #### 6. Generation of Knockout Mice * **Vector Design:** Flank critical exon(s) with loxP sites (for conditional knockout) or delete them directly. * **Outcome:** Produces non-functional gene product. * **Heterozygous (+/-):** Often phenotypically normal. * **Homozygous (-/-):** Displays null phenotype (can range from embryonic lethal to subtle changes). * **Conditional Knockouts:** Combine with Cre-loxP system to delete genes in specific tissues or at specific times (see Cre-loxP section). #### 7. Knockin Modifications * **Definition:** Insertion of new sequences at specific loci. * **Types:** * **Point Mutation Knockins:** Model human disease mutations (e.g., Alzheimer's, Parkinson's). * **Protein Tagging:** Insert GFP or other fluorescent proteins in-frame for visualization. * **Functional Domain Insertions:** Alter gene expression or protein function. #### 8. Advantages * **Precise Targeting:** Can target any specific chromosomal locus. * **Eliminates Position Effects:** Integration at known, specific site. * **Heritable:** Genetic modifications transmitted. * **Null Mutants:** Complete gene inactivation possible. * **Versatility:** Point mutations, tags, insertions all possible. #### 9. Limitations * **Technical Complexity:** Many steps, failure points. * **Time-consuming:** 6-12 months minimum. * **Labor-intensive:** Specialized facilities and personnel. * **Expensive:** High cost per experiment. * **Species Limitation:** Primarily for mice. * **Overall Efficiency:** Low (100-200 manipulations for one line). ### Integration & Expression Considerations Understanding how foreign DNA integrates and expresses is crucial for successful transgenesis. #### 1. Molecular Mechanisms of Integration * **Microinjection:** Injected DNA enters pronucleus, recognized as "foreign" by NHEJ machinery. Often forms tandem head-to-tail concatemers. * **Retroviral:** Well-understood viral integrase mechanism ("cut-and-paste"), highly efficient, stable insertion. * **ES Cell (Homologous Recombination):** Recognition of sequence homology, strand invasion, DNA synthesis, resolution of recombination intermediates. Random integration can occur if HR fails. #### 2. Position Effects & Chromatin Context * **Definition:** Influence of chromosomal location on transgene expression. * **Magnitude:** 10-100 fold expression differences for identical transgenes. * **Mechanism:** Chromatin environment affects transcription. * **Euchromatin (open):** Robust expression. * **Heterochromatin (closed):** Silenced expression (transgene variegation). * **Implication:** Requires screening multiple founder lines. #### 3. Locus Control Regions (LCRs) * **Definition:** DNA segments regulating gene expression over long distances (e.g., β-globin LCR). * **Function:** Establish and maintain transcriptionally active chromatin states. * **Improvement:** 5-10 fold increase in expression and reduced variation, but don't eliminate position effects. * **Challenge:** Large size (10-20 kb) and complex structure. #### 4. Chromatin Insulators & Boundary Elements * **Principle:** DNA elements blocking communication between enhancers/silencers and target genes. * **Function:** Prevent spread of chromatin modifications (e.g., repressive marks). * **Effectiveness:** Reduce variegation by 2-3 fold, modest improvement in consistency. #### 5. Transgene Size & Sequence Context * **Large Constructs (>20-30 kb):** Integrate less efficiently, higher rates of rearrangement, decreased microinjection success. * **Optimal Size:** 5-15 kb for highest efficiency. * **Sequence Context:** GC content, repetitive sequences, and CpG islands can affect silencing. ### Cre-loxP: Principles & Molecular Mechanisms The Cre-loxP system is a powerful tool for site-specific DNA recombination, enabling precise genetic manipulations. #### 1. Historical Development & Origins * **Source:** Bacteriophage P1. * **Natural Function:** Phage uses Cre-loxP for DNA replication and genome manipulation. * **Adaptation:** Widely adapted for use in model organisms from bacteria to mammals. #### 2. Structural Organization of Cre Recombinase * **Size:** 343 amino acids (~38 kDa). * **Structure:** Monomeric protein. * **Domains:** * **N-terminal (1-130 aa):** Helix-turn-helix DNA-binding motif, contacts loxP site. * **C-terminal (130-343 aa):** Catalytic machinery (Tyr324) for DNA cleavage and ligation. * **DNA Binding:** Induces DNA bending (~140°) at loxP sites. #### 3. Detailed Structure of loxP Sites * **Length:** 34 base pairs. * **Components:** * Two 13 bp inverted repeats (Cre binding sites). * 8 bp central spacer sequence (defines orientation). * **Directionality:** Spacer region determines orientation, crucial for recombination outcome. * **Orthogonal Variants:** Mutant loxP sites (e.g., lox511, lox2272) that don't recombine with wildtype loxP or each other, allowing multiple independent manipulations. #### 4. Mechanism of Cre-Mediated Recombination * **No Energy:** No ATP hydrolysis required. * **Specificity:** Highly specific. * **Reversibility:** Potentially reversible. * **Steps:** 1. **Complex Formation:** Cre binds to both loxP sites, bringing them together. 2. **DNA Cleavage:** Catalytic tyrosine cleaves phosphodiester backbone, forming covalent Cre-DNA intermediates. 3. **Strand Exchange:** DNA strands exchange mediated by the Cre-loxP complex. 4. **Resolution:** Remaining Cre-DNA intermediates resolved, Cre released, DNA nicks sealed. #### 5. Outcomes of Recombination The outcome depends on the relative orientation of the two loxP sites: * **Direct Repeats (same direction):** * **Outcome:** DELETION of intervening DNA. * **Product:** Excised DNA forms a circle, a single loxP site remains. * **Usage:** Basis of conditional knockout technology. * **Inverted Repeats (opposite direction):** * **Outcome:** INVERSION of intervening DNA segment. * **Product:** DNA between loxP sites is flipped. * **Usage:** Creating inducible switches. * **Chromosomal Translocations:** * **Outcome:** TRANSLOCATION (exchange of DNA) if loxP sites are on different chromosomes. * **Applications:** Model chromosomal rearrangements (e.g., in cancer). #### 6. Quantitative Aspects of Recombination Efficiency * **Efficiency:** 80-95% in tissues where Cre is expressed; 5-15% cells escape recombination. * **Incomplete Efficiency Causes:** Variations in Cre expression, cell cycle timing, chromatin accessibility. * **Modulation:** Increased Cre expression, multiple loxP sites, developmental stage timing, and optimization protocols can improve efficiency. ### Advanced Applications of Cre-loxP The Cre-loxP system enables precise control over gene manipulation, addressing limitations of conventional methods. #### 1. Conditional Knockouts: Tissue-Specific Gene Inactivation * **Problem Addressed:** Conventional knockouts are often embryonic lethal or lack tissue specificity. * **Solution:** Restrict gene disruption to specific tissues or developmental stages. * **Floxed Alleles:** Target gene's critical exon(s) are "floxed" (flanked by loxP sites) using ES cell targeting. These mice are phenotypically normal until Cre is present. * **Tissue-Specific Cre:** Transgenic mice express Cre under a tissue-specific promoter (e.g., Nestin-Cre for CNS, Albumin-Cre for liver). * **Cross Strategy:** Cross tissue-specific Cre line with floxed allele carrier. F1 offspring have gene deleted specifically in the tissue where Cre is expressed. * **Example:** Nestin-Cre x floxed gene → gene deleted in neurons, allowing study of neuronal function despite potential embryonic lethality. #### 2. Inducible Knockouts: Temporal Control * **Problem Addressed:** Conditional knockouts inactivate genes from early development. Temporal control is needed to study adult-specific functions. * **Solution:** Drug-triggered gene inactivation. * **Tamoxifen-Inducible CreER System:** * **Protein Design:** Cre recombinase fused to a modified estrogen receptor (ER). * **Basal State:** CreER is in cytoplasm, bound to heat shock proteins, inactive. * **Activated State:** Tamoxifen binds ER, causes conformational change, CreER enters nucleus and recombines loxP sites. * **Kinetics:** Recombination occurs rapidly (hours) after tamoxifen administration. * **Implementation:** CreER expressed tissue-specifically or ubiquitously. Tamoxifen administration triggers gene deletion on demand. * **Advantages:** Overcomes developmental lethality, provides temporal resolution, allows study of acute vs. chronic effects. #### 3. Lineage Tracing & Cell Fate Determination * **Principle:** Permanently mark cells and their progeny to track cell populations. * **Transgene Design:** loxP-flanked STOP cassette blocking a reporter gene (e.g., `lacZ` or GFP). * **Mechanism:** Cre recombinase excises the STOP cassette, activating reporter gene expression. The reporter is then permanently expressed in that cell and all its descendants. * **Combination:** Coupled with tissue-specific or inducible Cre drivers for precise marking. * **Applications:** * **Developmental Biology:** Mapping neural lineages, investigating developmental origins, organ formation. * **Adult Tissue Homeostasis:** Identifying stem cell dynamics (e.g., intestinal stem cells), hematopoietic system, hair follicle. * **Tumor Biology:** Identifying origins and clonal evolution of tumors. #### 4. Intersectional Genetics: Combining Multiple Cre-loxP Systems * **Goal:** Achieve highly specific cell-type targeting beyond single promoter specificity. * **Strategy:** Require activity of multiple genetic drivers for transgene activation. * **Cre-loxP with Flp-FRT System:** Transgenes contain both loxP and FRT sites. Activation requires both Cre and Flp recombinases, leading to activation only in cells expressing both. * **Double-Transgenic Cre Systems:** Reporter activated only in cells expressing two independent Cre drivers. * **Outcome:** Dramatically increased specificity, approaching single-cell resolution for certain cell types, reducing off-target labeling. ### Cre-loxP: Practical Considerations & Limitations While powerful, the Cre-loxP system has technical challenges that require careful consideration. #### 1. Efficiency of Recombination * **Incompleteness:** Typically 5-15% of cells escape recombination, even under optimal conditions. * **Impact:** Conditional knockouts are technically partial knockdowns. May affect phenotype interpretation, especially if complete gene inactivation is required. * **Improvement:** Use multiple Cre lines, strongly expressed inducible Cre, optimize activation conditions. #### 2. Off-Target Recombination * **Issue:** At high expression, Cre can recombine with imperfect loxP-like sequences in the genome. * **Consequence:** May disrupt essential genes, cause unexpected phenotypes, complicate interpretation. * **Minimization:** Limit Cre expression, screen for unintended events, verify target-specific recombination. #### 3. Context Dependence of Cre Expression * **Position Effects:** Cre transgene expression pattern and level are influenced by integration site. * **Variability:** Tissue-specific promoters may show different patterns or levels of expression in different Cre lines. * **Characterization:** Each Cre transgenic line must be thoroughly characterized (e.g., by crossing with a loxP-flanked reporter) to confirm expression pattern. #### 4. Developmental Toxicity * **Phenomenon:** Some Cre transgenes cause developmental abnormalities independent of loxP recombination (e.g., off-target recombination or Cre overexpression). * **Effects:** Lethality, reduced survival, growth retardation. * **Necessity:** Careful characterization of Cre lines for toxicity; use control crosses. #### 5. Design Considerations for Gene Targeting * **Exon Selection:** Floxed exon(s) must be essential for gene function. Minimizing floxed segment size improves efficiency. * **Specificity of Cre Drivers:** Choose drivers matching biological interest and verify their expression pattern, including developmental timing. * **Genetic Background:** Phenotypes are affected by genetic background. Conditional knockouts should be generated and maintained in a defined genetic background (e.g., C57BL/6). #### 6. Limitations of Cre-loxP Systems * **Incomplete Recombination:** Not 100% efficient, leading to residual gene expression. * **Immunogenicity:** loxP sequences can sometimes trigger immune responses. * **Position Effects:** Cre transgenes themselves are subject to position effects, leading to variability between lines. * **Lack of Absolute Specificity:** Promoter leakage can lead to Cre expression in unintended tissues; inducible systems may show background recombination. #### 7. Future Developments * **CRISPR/Cas9:** Offers faster, more efficient genome editing, complementing or replacing Cre-loxP for many applications. * **Alternative Systems:** dre-rox, phiC31-att provide orthogonal tools for complex manipulations. * **Synthetic Biology:** Construction of sophisticated genetic circuits with multiple recombination events. * **Continued Refinement:** Ongoing improvements in specificity and efficiency. ### Viral & Non-Viral Vector Systems Vectors are engineered carriers for delivering foreign DNA into animal cells, crucial for gene therapy and research. #### 1. General Principles of Vector Design * **Function:** Deliver DNA, cross membranes, minimize immune response, provide regulatory sequences, include selectable markers, enable recombination. * **Optimization:** Specific design for specific applications. #### 2. Viral Vectors Exploit viruses' natural cell entry machinery, with replication genes removed and replaced with cargo. * **Retroviral Vectors:** (See earlier section) Integrate into host genome, infect dividing cells. * **Lentiviral Vectors:** * **Source:** Subfamily of retroviruses. * **Key Difference:** Can transduce non-dividing cells (e.g., neurons) due to Vpr protein. * **Properties:** Stable integration, up to ~8 kb insert, broad tropism. * **Applications:** Brain transduction, transgenic animal generation, gene therapy. * **Adenoviral Vectors:** * **Genome:** Non-enveloped, dsDNA (~36 kb). * **Characteristics:** High titers, high transduction efficiency, non-integrating (episomal), triggers strong immune response. * **Limitations:** Transient expression, immunogenicity. * **Use:** Applications requiring transient expression and high efficiency. * **Adeno-Associated Viral Vectors (AAV):** * **Genome:** Small DNA virus (~4.7 kb), restricts insert capacity (~4-5 kb). * **Advantages:** Low immunogenicity, safe profile, long-term transgene persistence, efficient transduction of many tissues (especially neurons). * **Serotypes:** >100 natural serotypes and engineered variants for diverse tissue targeting. * **Current Status:** Preferred for emerging clinical gene therapies. #### 3. Non-Viral Vectors (Physical Transfection Methods) Generally lower efficiency than viral vectors, but less immunogenic and can accommodate larger inserts. * **Plasmid DNA & Microinjection:** Direct injection of naked plasmid DNA. Low efficiency (1-5%), transient expression. Used in embryo transgenesis. * **Lipofection:** DNA complexes with cationic liposomes, endocytosed by cells. 10-50% efficiency in cultured cells, lower in vivo. Non-viral, large insert capacity. * **Electroporation:** Electrical pulses create transient membrane permeability. 5-20% efficiency in ES cells, variable in vivo. No viral components. * **Calcium Phosphate & Chemical Transfection:** Forms DNA-calcium phosphate coprecipitate, ingested by cells. 5-15% efficiency. Largely superseded by newer methods. #### 4. Targeting Vectors for Homologous Recombination (See ES Cell Method Section) These vectors use homology arms, a modified gene sequence, and positive/negative selection markers to mediate precise integration into the genome. ### Site-Specific Recombination Beyond Cre-loxP Beyond Cre-loxP, other site-specific recombination (SSR) systems offer orthogonal tools for complex genetic manipulations. #### 1. The Flp-FRT Recombination System * **Origin:** Saccharomyces cerevisiae (baker's yeast). * **Components:** Flp recombinase recognizes FRT (Flp Recognition Target) sites (34 bp). * **Mechanism:** Identical to Cre-loxP (deletion, inversion, translocation depending on FRT orientation). * **Orthogonality:** No cross-reactivity with Cre-loxP, allowing both systems to be used independently in the same animal. * **Efficiency:** Slightly less robust than Cre-loxP in vivo. * **Applications:** Intersectional approaches (requiring both Cre and Flp for activation) for increased specificity. #### 2. The Dre-rox System * **Origin:** Bacteriophage D6. * **Components:** Dre recombinase recognizes rox sites (34 bp). * **Orthogonality:** Complete orthogonality to both Cre-loxP and Flp-FRT. * **Potential:** Enables triple independent control for highly complex genetic manipulations. Less extensively developed. #### 3. The phiC31 Att-Site System * **Origin:** Streptomyces bacteriophage phiC31. * **Unique Characteristics:** * **Site Non-equivalence:** Recombination between attP (phage-type) and attB (bacterial-type) sites. * **Directionality:** Always attP + attB. * **Irreversibility:** Back-reaction is essentially absent. * **phiC31 Integrase:** Catalyzes the recombination. * **Applications:** Site-specific transgenesis, moving transgenes from random integration sites to defined chromosomal locations to reduce position effects. #### 4. Applications of Multiple Recombination Systems * **Intersectional Precision:** Combining Cre-loxP, Flp-FRT, and Dre-rox allows for activation of transgenes only in cells expressing multiple recombinases, achieving unprecedented cell-type specificity. * **Complex Genetic Engineering:** Enables multiple simultaneous modifications and independent control of multiple loci for sophisticated genetic manipulations and disease modeling. ### Genomic Insulation & Regulatory Elements (This topic is covered in Lecture 4-5 "Integration and Expression Considerations".) ### Somatic Cell Nuclear Transfer (SCNT) & Animal Cloning SCNT is a technology that demonstrates the reversibility of cellular differentiation, allowing the creation of genetically identical organisms. #### 1. Introduction & Biological Significance * **Dolly the Sheep (1996):** First mammalian clone, proving a differentiated cell nucleus can support full organism development. * **Reprogramming:** Egg cytoplasm factors can erase epigenetic modifications of a somatic nucleus, restoring pluripotency. * **Molecular Basis:** Involves remodeling DNA methylation and histone modification patterns, reactivating embryonic genes. #### 2. Detailed SCNT Procedure 1. **Egg Collection & Preparation:** * Mature oocytes (metaphase II) collected. * Enucleation: Metaphase II spindle and chromosomes removed using a micropipette. 2. **Somatic Cell Preparation:** * Donor cells (e.g., fibroblasts) cultured and synchronized to G0/G1 phase. * Nucleus extracted. 3. **Nucleus Transfer:** * Somatic cell nucleus injected into the enucleated oocyte. * Nucleus is placed in contact with the oocyte cytoplasm. 4. **Activation:** * Oocyte activated to exit metaphase II arrest (e.g., electrical stimulation, chemical agents). * Mimics calcium signaling from sperm entry, initiating embryonic development. 5. **Embryo Development & Transfer:** * Activated embryo cultured in vitro to blastocyst stage. * Viable blastocysts transferred into the uterus of a hormonally receptive recipient female (surrogate mother). * Full gestation for birth of cloned offspring. #### 3. Efficiency & Success Rates * **Overall Efficiency:** Typically 1-3% of manipulated oocytes produce live-born clones. * **Bottlenecks:** Low efficiency at multiple steps (enucleation, reprogramming, embryonic development, fetal development). * **Source Material:** Efficiency varies with donor cell type (embryonic/fetal cells > adult differentiated cells). #### 4. Developmental Abnormalities & Health Issues * **Large Offspring Syndrome (LOS):** Abnormal fetal and placental growth, excessive fetal size, organ weight abnormalities. Leads to stillbirths or neonatal deaths. * **Post-Natal Complications:** Immune dysfunction, reproductive abnormalities, premature aging, metabolic dysfunction. * **Mechanisms:** Primarily due to incomplete epigenetic reprogramming, leading to abnormal gene expression patterns, especially of imprinted genes. #### 5. Genomic Imprinting Defects * **Genomic Imprinting:** Parent-of-origin-specific epigenetic modification (some genes expressed from maternal, others from paternal chromosome). * **Defects in Clones:** Imprinting erasure and re-establishment are often imperfect, leading to abnormal expression of imprinted genes (e.g., IGF2, H19). * **Consequences:** Directly linked to growth dysregulation, metabolic dysfunction, and developmental abnormalities observed in clones. #### 6. Applications of Cloning in Livestock * **Combination with Genetic Modification:** Modify somatic cells in culture (e.g., gene targeting), then clone the modified cell to create transgenic livestock with precise genetic changes. * **Pharmaceutical Protein Production ("Molecular Farming"):** Transgenic animals express human proteins in milk (e.g., Protein C from goats, Factor VIII from cattle). Provides a potentially cost-effective, large-scale, and naturally post-translationally modified source of biologics. * **Genetic Preservation & Trait Multiplication:** Preserve superior genetic traits and rapidly multiply animals with desirable phenotypes. #### 7. Challenges & Future Directions * **Fundamental Challenge:** Incomplete and imperfect reprogramming remains the limiting factor, causing low efficiency and abnormalities. * **Improvements:** Modest gains from better culture media and optimized protocols. * **Alternative Approaches:** iPSCs, CRISPR/Cas9 gene editing (especially combined with SCNT) offer more efficient and precise alternatives. * **Regulatory & Ethical Concerns:** Public perception, ethical debates, and regulatory complexities limit widespread adoption. ### Nuclear Transfer in Livestock & Practical Considerations SCNT is applied in various livestock species, though efficiency and practical utility vary. #### 1. Species-Specific Variations in SCNT Efficiency * **Cattle Cloning:** ~1-3% efficiency. Routinely performed for research and commercial applications (e.g., transgenic cattle for pharming). * **Sheep Cloning:** ~1-2% efficiency. Extensively used for research since Dolly. * **Porcine (Pig) Cloning:** More difficult, lower efficiencies due to oocyte biology differences. * **Caprine (Goat) Cloning:** Variable efficiency, demonstrated successfully. * **Mechanism:** Differences in oocyte-specific factors, embryonic genome activation timing, and placental development contribute to species variation. #### 2. SCNT Combined with Genetic Engineering * **Strategy:** Genetically modify somatic cells in culture (e.g., knockout, overexpression), then use these modified cells for SCNT. * **Advantages:** Precision (exact genetic modifications), predictability (no random integration), avoids screening for appropriate expression. * **Applications:** * **Allergen Reduction:** Knockout genes encoding major allergens in milk (e.g., casein). * **Heterologous Protein Expression:** Engineer livestock to express human proteins in specific tissues. * **Disease Model Creation:** Introduce human disease mutations into livestock (e.g., cattle, pigs) to study pathophysiology. #### 3. Large Livestock: Cattle Cloning * **Development:** First cloned in 1998, protocols continuously refined. * **Prevalence:** Widely used for research, genetic preservation, and generating transgenic cattle. * **Health Complications:** LOS is common, high mortality, immune dysfunction, metabolic issues, reduced lifespan limit commercial utility. * **Economics:** High costs and health issues limit widespread adoption in commercial agriculture, making it more valuable in research. #### 4. Pharmaceutical Protein Production Through Transgenic Livestock * **Strategy:** Transgenic animals express human proteins in milk, which is then harvested and purified. * **Advantages:** Potentially lower cost, self-renewing production, natural protein folding and post-translational modifications, large-scale production. * **Examples:** Protein C (anticoagulant), Factor VIII/IX (hemophilia treatment), fibrinogen. * **Cloning Application:** SCNT establishes herds of genetically identical transgenic animals, ensuring uniform protein production. * **Regulatory Pathway:** FDA has approved some transgenic animal-derived pharmaceuticals. * **Economic Viability:** Dependent on the value of the protein; high-value therapeutics are more viable. #### 5. Advantages & Limitations of Livestock Cloning * **Potential Advantages:** Rapid establishment of genetically superior animals, multiplication of valuable genetics, precise genetic modifications, consistent genetics in herds, pharmaceutical protein production. * **Significant Limitations:** Low efficiency (1-3%), high cost, frequent health problems (LOS, reduced lifespan), ethical concerns, public perception issues, labor-intensive. #### 6. Limitations & Future of Technology * **Technological Bottleneck:** Incomplete and imperfect reprogramming remains the core problem. * **Alternative Technologies:** CRISPR/Cas9 and gene editing are becoming preferred for their higher efficiency, shorter timelines, and lower cost. Artificial gamete production and spermatogenic stem cell transgenesis are emerging. * **Niche Applications:** SCNT remains valuable for precise genetic modification combined with cloning, and for pharmaceutical protein production in livestock. * **Research Contributions:** SCNT has provided fundamental insights into developmental biology, epigenetic reprogramming, and pluripotency. ### Green Fluorescent Protein (GFP): Discovery, Mechanism, & Properties GFP revolutionized cell biology by allowing visualization of biological processes in living systems. #### 1. Discovery & Biological Origin * **Source:** Jellyfish *Aequorea victoria* (1960s, Osamu Shimomura). * **Natural Function:** Associated with bioluminescence, converting blue light from aequorin to green light. * **Breakthrough (1990s):** Roger Tsien and others discovered its molecular mechanism. #### 2. Mechanism of GFP Fluorescence * **Protein Structure:** 238 amino acids (~27 kDa) forming a characteristic β-barrel structure, protecting the chromophore. * **Chromophore Composition:** Formed by autocatalytic post-translational modification of Ser-65, Tyr-66, Gly-67 within the β-barrel. This process requires only protein folding and molecular oxygen, no external cofactors. * **Chromophore Function:** * **Absorption:** Peak at ~488 nm (green region). * **Emission:** Peak at ~509 nm (green light). * **Quantum Yield:** ~0.79 (high efficiency). #### 3. Properties & Characteristics of GFP * **Ideal Properties:** Brightness, photostability, non-toxic, genetically encoded, subcellular targeting, no cofactor required, universal applicability, self-sufficient. * **Maturation Process:** Requires ~1 hour at 37°C for chromophore formation after synthesis. * **pH Dependence:** Optimal at neutral to slightly basic pH (pKa ~6); reduced fluorescence in acidic environments. * **Environmental Independence:** Largely unaffected by post-translational modifications or cellular redox state. #### 4. Spectral Variants & Engineered GFP Derivatives * **Motivation:** Overcome single-wavelength limitation for multi-color imaging. * **Cyan Fluorescent Protein (CFP):** Blue-shifted (excitation ~435 nm, emission ~475 nm). * **Yellow Fluorescent Protein (YFP):** Red-shifted (excitation ~515 nm, emission ~527 nm). * **Red Fluorescent Proteins (e.g., mCherry):** From sea coral, further red-shifted (excitation ~587 nm, emission ~610 nm), improved photostability. * **Far-Red Fluorescent Proteins (e.g., iRFP):** Emission >700 nm, allowing deeper tissue penetration. * **Utility:** Enables multi-color imaging (3-4+ proteins simultaneously) to visualize complex cellular processes. #### 5. Fluorescent Protein Fusions & Applications * **Concept:** Fusion protein = protein of interest + fluorescent protein. Transgene expresses the fusion, which localizes like the native protein. * **Advantage:** Live-cell imaging, real-time dynamics, observing protein movement and interactions. * **Examples:** Synaptotagmin-GFP (synaptic vesicles), membrane protein fusions (membrane dynamics), Histone-GFP (chromatin), Actin-GFP (cytoskeleton). * **Applications:** Protein trafficking, subcellular localization, protein-protein interactions (FRET), gene expression, signal transduction. #### 6. Limitations of GFP * **Size:** ~27 kDa, can interfere with fusion protein function, especially for small proteins. * **Maturation Delay:** ~1 hour, limits temporal resolution for fast processes. * **pH Sensitivity:** Fluorescence varies with local pH, complicating comparisons across compartments. * **Photostability:** Less photostable than some synthetic dyes, can photobleach during long-term imaging. ### GFP Applications in Transgenic Animals & Biosensing GFP and its variants are invaluable tools for visualizing biological processes, from gene expression to environmental sensing. #### 1. GFP as a Reporter Gene in Transgenic Animals * **Basic Use:** Promoter driving GFP expression confirms successful transgenesis and reveals expression pattern. * **Whole-Body Imaging:** Constitutive GFP allows non-invasive, whole-animal visualization of expression. * **Tissue-Specific Reporters:** GFP under tissue-specific promoters confirms tissue-specific gene expression and aids developmental studies. * **Inducible Systems:** Cre-dependent GFP activation (loxP-STOP-GFP) allows temporal and spatial control of reporting. #### 2. GFP-Based Lineage Tracing * **Principle:** Permanent genetic marking of cells and their progeny. * **Mechanism:** Cre recombinase excises a loxP-flanked STOP cassette, activating GFP expression in the cell and all its descendants. * **Applications:** Mapping neural progenitor fates, tracking stem cell dynamics, identifying tumor clonal origins. #### 3. GFP-Based Biosensors * **Concept:** Transgenic organisms fluoresce in response to specific stimuli (e.g., environmental contaminants, biological signals). * **GFP-Based Estrogen Biosensor:** Transgenic Medaka fish with GFP under a vitellogenin promoter. Estrogenic contaminants trigger GFP expression even in males, providing a visual indicator of pollution. * **Other Biosensors:** For heavy metals, polyaromatic hydrocarbons, oxidative stress, thermal stress (using stress-response gene promoters). #### 4. Fluorescent Protein Biosensors Based on Conformational Changes * **Advanced Design:** Fluorescent proteins engineered to change brightness or color in response to biochemical events (e.g., enzyme activity, protein-protein interactions). * **FRET-Based Biosensors:** * **Mechanism:** Two fluorescent proteins (e.g., CFP and YFP) are positioned to undergo Förster Resonance Energy Transfer (FRET) when they are in close proximity (e.g., due to protein interaction or conformational change). * **Detection:** Change in FRET efficiency (ratio of YFP/CFP emission) indicates biological activity. * **Applications:** Detecting kinase activity, protease activity, protein-protein interactions, signal transduction in living cells or transgenic animals. #### 5. GFP in Studying Gene Expression * **Reporter Gene Applications:** * **Promoter Activity:** GFP under a gene promoter indicates where and when the gene is expressed. * **Developmental Mapping:** Tracking gene expression during development. * **Responsive Genes:** Revealing tissues experiencing stress or responding to stimuli. * **Dynamic Studies:** Time-lapse imaging to observe changes in expression patterns. * **Spatial Mapping:** Identifying gene expression at tissue or subcellular resolution. #### 6. "GloFish" & Commercial Applications * **Product:** Transgenic zebrafish and other fish species expressing fluorescent proteins (GFP, RFP, YFP) under constitutive or muscle-specific promoters. * **Commercial Significance:** First transgenic organism sold commercially for a non-therapeutic purpose (ornamental aquarium fish). * **Regulatory Precedent:** FDA approval for AquAdvantage Salmon (growth hormone transgenic) established regulatory pathways for transgenic animals in food. * **Ethical Considerations:** Concerns about welfare, environmental escape risk, and public perception. #### 7. Future Directions & Emerging Technologies * **Synthetic Organic Fluorophores:** Offer higher brightness, photostability, and smaller size than FPs. * **Super-Resolution Microscopy:** Specialized techniques (STED, PALM, STORM) overcome diffraction limits, enabling near-molecular scale visualization with FPs. * **Expansion Microscopy:** Chemically expands tissue for subdiffraction-resolution imaging. * **Advancing Palette:** Continued development of FPs with improved properties, expanded spectral range, and increased sophistication (e.g., calcium-sensitive variants). * **Integration:** FPs are integrated with CRISPR, optogenetics, and computational approaches for advanced research. ### Transgenic Fish & Unique Advantages Fish are powerful model organisms for transgenesis due to their unique developmental and reproductive characteristics. #### 1. Introduction to Fish as Transgenic Models * **Common Models:** Zebrafish (*Danio rerio*), Medaka (*Oryzias latipes*), Tilapia, Salmon/Trout. * **Unique Advantages:** * **Large Egg Numbers:** Hundreds of externally fertilized eggs. * **External Development:** Direct observation of development without dissection. * **Transparent Embryos:** Especially zebrafish larvae, allow visualization of internal structures and real-time observation. * **Rapid Development:** Quick generation times (weeks to months). * **Genetic Tractability:** Well-mapped genomes, classic genetic tools. * **Scalability & Cost-Effectiveness:** Easy to maintain large numbers. * **Amenability to Screening:** Large-scale genetic and chemical screens possible. #### 2. Methodologies for Fish Transgenesis * **Microinjection (Primary):** * **Target:** One-cell stage fertilized egg (large, robust, easily visible). * **Procedure:** DNA injected directly into the pronuclear region. * **Efficiency:** High survival (25-50%) and integration rates (1-5%). * **Dominant Method:** Due to ease and efficiency. * **Electroporation (Alternative):** Brief electrical pulse for DNA entry. Lower efficiency but faster and less invasive. * **Other Methods:** Sperm-mediated transgenesis, gene gun (less common). #### 3. Integration & Expression Characteristics * **Integration Pattern:** Random, often tandem concatemers, similar to mammalian microinjection. * **Expression:** Influenced by position effects, requiring founder line screening. * **Advantage:** Faster generation time allows quicker establishment and screening of lines. #### 4. Growth Enhancement & Aquaculture Applications * **Growth Hormone Transgenic Fish:** * **Concept:** Overexpression of growth hormone (GH) using extra copies of GH genes (native or heterologous). * **Example:** AquAdvantage Salmon (FDA-approved). Chinook salmon GH gene under ubiquitin promoter leads to 25,000-fold overexpression and growth to harvest size in 18 months (vs. 36 months). * **Economic Advantage:** Reduced production time, lower feed costs, faster economic return. * **Commercial Adoption:** Limited due to market resistance and consumer perception. * **Regulatory Approval:** AquAdvantage Salmon was the first GM animal approved for human food (2015), determined to be substantially equivalent. #### 5. Cold Tolerance & Environmental Resistance * **Antifreeze Protein Transgenics:** * **Strategy:** Introduce antifreeze protein (AFP) genes from cold-water fish (e.g., Winter flounder). * **Mechanism:** AFPs inhibit ice crystal formation. * **Application:** Transgenic salmon/trout can survive colder water, expanding aquaculture geographic range. * **Salinity Tolerance:** Engineering tolerance to high-salinity for saltwater aquaculture. #### 6. Research Applications & Behavioral Studies * **GFP Reporter Transgenics:** Larval transparency allows visualization of internal GFP expression, cell-type identification, and real-time observation of development. Brainbow transgenics enable tracking individual neurons. * **Optogenetics:** Expressing light-activated ion channels in specific neurons to manipulate neural circuits and observe behavior. Fish transparency and rapid assays are advantageous. * **Large-Scale Genetic Screening:** Saturation mutagenesis combined with high-throughput screening of transparent larvae identifies genes essential for development, neural function, and behavior (e.g., in zebrafish). * **Disease Modeling:** Introducing human disease mutations into fish (e.g., cancer, neurodevelopmental disorders) for whole-organism disease modeling with rapid development and behavioral readouts. #### 7. Ecological & Regulatory Concerns * **Escape Risk:** Primary concern is transgenic fish escaping into wild populations, potentially interbreeding or causing ecological unpredictability. * **Containment:** Strict containment requirements (e.g., multiple levels, geographic isolation) for facilities. AquAdvantage Salmon uses triploidy (sterility) to prevent reproduction. * **Environmental Assessment:** FDA evaluates potential environmental impacts and risks. * **Consumer & Regulatory Landscape:** Varies by jurisdiction (e.g., EU more restrictive than USA). Market acceptance is mixed, and labeling requirements differ.